{"id":160,"date":"2026-05-07T14:55:50","date_gmt":"2026-05-07T14:55:50","guid":{"rendered":"https:\/\/stevenenergyplus.com\/SRCE\/?page_id=160"},"modified":"2026-05-11T17:43:50","modified_gmt":"2026-05-11T17:43:50","slug":"siga","status":"publish","type":"page","link":"https:\/\/stevenenergyplus.com\/SRCE\/?page_id=160","title":{"rendered":"$SIGA"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-1024x683.jpg\" alt=\"\" class=\"wp-image-248\" srcset=\"https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-1024x683.jpg 1024w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-300x200.jpg 300w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-768x512.jpg 768w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-1536x1024.jpg 1536w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-2048x1365.jpg 2048w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/national-cancer-institute-NFvdKIhxYlU-unsplash-600x400.jpg 600w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Outlook<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>SIGA expects to deliver $13 mln of oral TPOXX to an international customer in Q2 2026<\/li>\n\n\n\n<li>Company plans to deliver $26 mln of IV TPOXX to U.S. Government by end of Q3 2026<\/li>\n\n\n\n<li>SIGA says focus remains on securing new procurement contracts and orders to drive business<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><br>Result Drivers<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>INTERNATIONAL EXPANSION &#8211; Co signed exclusive license agreement for oral TPOXX in MENA region<\/li>\n\n\n\n<li>UPCOMING CONTRACT DELIVERIES &#8211; Co expects to deliver $13 mln of oral TPOXX to Asia Pacific customer in Q2 and $26 mln of IV TPOXX to U.S. government by end of Q3<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"313\" src=\"https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-215348-1024x313.png\" alt=\"\" class=\"wp-image-171\" srcset=\"https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-215348-1024x313.png 1024w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-215348-300x92.png 300w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-215348-768x235.png 768w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-215348-1536x469.png 1536w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-215348.png 1562w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"796\" height=\"779\" src=\"https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-123803.png\" alt=\"\" class=\"wp-image-169\" srcset=\"https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-123803.png 796w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-123803-300x294.png 300w, https:\/\/stevenenergyplus.com\/SRCE\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-07-123803-768x752.png 768w\" sizes=\"auto, (max-width: 796px) 100vw, 796px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/siga.com\" data-type=\"link\" data-id=\"siga.com\">SIGA Technologies<\/a> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ticker: <a href=\"https:\/\/us.etrade.com\/etx\/mkt\/quotes?symbol=siga#\/snapshot\" data-type=\"link\" data-id=\"https:\/\/us.etrade.com\/etx\/mkt\/quotes?symbol=siga#\/snapshot\">$SIGA<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sector: Healthcare<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry: Pharmaceuticals<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Headquarters31 East 62Nd Street<br>New York, NY<br>10065<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Outlook Result Drivers SIGA Technologies Ticker: $SIGA Sector: Healthcare Industry: Pharmaceuticals SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-160","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=\/wp\/v2\/pages\/160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=160"}],"version-history":[{"count":9,"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=\/wp\/v2\/pages\/160\/revisions"}],"predecessor-version":[{"id":251,"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=\/wp\/v2\/pages\/160\/revisions\/251"}],"wp:attachment":[{"href":"https:\/\/stevenenergyplus.com\/SRCE\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}